In accordance
with 5 CFR 1320, the information collection is approved. However,
the agency must submit a final version of the instrument (as it
will be fielded) prior to beginning the study.
Inventory as of this Action
Requested
Previously Approved
11/30/2015
36 Months From Approved
14,338
0
0
1,873
0
0
0
0
0
This project will investigate the
effects of adding disease information to branded prescription drug
promotional materials on consumer perceptions and understanding.
Part of FDA's public health mission is to ensure the safe use of
prescription drugs; therefore it is important to communicate the
risks and benefits of prescription drugs to consumers in a way that
is clear, useful and non-misleading. The results from this project
will be used by FDA to inform its understanding of DTC advertising,
inform regulatory policy, and may also help to identify areas for
further research.
US Code:
42 USC 300u(a)(4) Name of Law: Section 1701(a)(4) - Public
Health Service Act
US Code:
21 USC 393(d)(2)(c)) Name of Law: Federal Food, Drug, and
Cosmetic Act (the FD&C Act)
Johnny Vilela 301 796-3792
juanmanuel.vilela@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.